Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics

Reuters

昨天

Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics

Overview

Diagnostic solutions firm's preliminary Q4 revenue rose 41%, beating analyst expectations
Company affirms guidance for positive Adjusted EBITDA in Q4 2025
Lung Diagnostics revenue grew 47% in Q4, driven by test volume and reimbursement expansion

Outlook

Biodesix affirms positive Adjusted EBITDA expectation for Q4 2025
Company sees momentum building into 2026

Result Drivers

LUNG DIAGNOSTICS GROWTH - Revenue from Lung Diagnostics increased by 47% in Q4, driven by higher test volumes and expanded reimbursement
DEVELOPMENT SERVICES REVENUE - Development Services revenue grew by 13% in Q4, contributing to overall revenue growth

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Beat	$28.80 mln	$24.85 mln (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Biodesix Inc is $35.00, about 541% above its January 9 closing price of $5.46

Press Release: ID:nGNX1CsNVy

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2602519547"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602519547\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602519547?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602519547","market":"nz","top_or_hot":-1,"title":"Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics </title></head><body><p><span>Overview</span></p><ul><li><p>Diagnostic solutions firm's preliminary Q4 revenue rose 41%, beating analyst expectations</p></li><li><p>Company affirms guidance for positive Adjusted EBITDA in Q4 2025</p></li><li><p>Lung Diagnostics revenue grew 47% in Q4, driven by test volume and reimbursement expansion</p></li></ul><p><span>Outlook</span></p><ul><li><p>Biodesix affirms positive Adjusted EBITDA expectation for Q4 2025</p></li><li><p>Company sees momentum building into 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LUNG DIAGNOSTICS GROWTH - Revenue from Lung Diagnostics increased by 47% in Q4, driven by higher test volumes and expanded reimbursement</p></li><li><p>DEVELOPMENT SERVICES REVENUE - Development Services revenue grew by 13% in Q4, contributing to overall revenue growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$28.80 mln</p></td><td><p>$24.85 mln (5 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the healthcare facilities &amp; services peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Biodesix Inc is $35.00, about 541% above its January 9 closing price of $5.46</p></li></ul><p>Press Release: <span>ID:nGNX1CsNVy</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 19:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics </title></head><body><p><span>Overview</span></p><ul><li><p>Diagnostic solutions firm's preliminary Q4 revenue rose 41%, beating analyst expectations</p></li><li><p>Company affirms guidance for positive Adjusted EBITDA in Q4 2025</p></li><li><p>Lung Diagnostics revenue grew 47% in Q4, driven by test volume and reimbursement expansion</p></li></ul><p><span>Outlook</span></p><ul><li><p>Biodesix affirms positive Adjusted EBITDA expectation for Q4 2025</p></li><li><p>Company sees momentum building into 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LUNG DIAGNOSTICS GROWTH - Revenue from Lung Diagnostics increased by 47% in Q4, driven by higher test volumes and expanded reimbursement</p></li><li><p>DEVELOPMENT SERVICES REVENUE - Development Services revenue grew by 13% in Q4, contributing to overall revenue growth</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$28.80 mln</p></td><td><p>$24.85 mln (5 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the healthcare facilities &amp; services peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Biodesix Inc is $35.00, about 541% above its January 9 closing price of $5.46</p></li></ul><p>Press Release: <span>ID:nGNX1CsNVy</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nL1N3YD0B0:1","article_id":"2602519547","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602519547","pubTimestamp":1768216216,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung DiagnosticsOverviewDiagnostic solutions firm's preliminary Q4 revenue rose 41%, beating analyst expectationsCompany affirms guid","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","BDSX":"Biodesix, Inc."},"translate_title":"得益于肺部诊断领域的增长，Biodesix prelim第四季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BDSX":0.9},"content_text":"Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics OverviewDiagnostic solutions firm's preliminary Q4 revenue rose 41%, beating analyst expectationsCompany affirms guidance for positive Adjusted EBITDA in Q4 2025Lung Diagnostics revenue grew 47% in Q4, driven by test volume and reimbursement expansionOutlookBiodesix affirms positive Adjusted EBITDA expectation for Q4 2025Company sees momentum building into 2026Result DriversLUNG DIAGNOSTICS GROWTH - Revenue from Lung Diagnostics increased by 47% in Q4, driven by higher test volumes and expanded reimbursementDEVELOPMENT SERVICES REVENUE - Development Services revenue grew by 13% in Q4, contributing to overall revenue growthKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueBeat$28.80 mln$24.85 mln (5 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the healthcare facilities & services peer group is \"buy\"Wall Street's median 12-month price target for Biodesix Inc is $35.00, about 541% above its January 9 closing price of $5.46Press Release: ID:nGNX1CsNVyFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}